New method for analyzing intact tumor samples to be used for studying COVID-19

NewsGuard 100/100 Score

Researchers at Karolinska Institutet in Sweden have developed a new method for analyzing intact tumor samples in 3D on a molecular level. The study is a collaboration with Karolinska University Hospital and is published in Nature Biomedical Engineering. Now the researchers are planning to use the method to study tissue samples from COVID-19 patients in the hope that it will provide information on where and how the new coronavirus attacks different organs.

Cancer is caused when vital molecular mechanisms in cells stop operating normally. To better understand these pathological processes, scientists need to study what occurs in tumor cells at an RNA and protein level. RNA acts as a messenger between the genes and the proteins that they code for, and there are different kinds of RNA involved in cancer.

The researchers have applied a new imaging technique, which is used in basic research, to study intact - rather than sectioned - human tumor tissue. The technique involves making the tissue transparent, staining different kinds of RNA and proteins, and then imaging the tissue in three dimensions using an instrument called a light-sheet microscope. Doing this, it is possible to determine where in the tumor there are abnormal amounts of RNA or protein. The method, called DIIFCO, facilitates the study of cancer-related mechanisms and enables more exact diagnoses of tissue samples from cancer patients.

More exact cancer diagnoses

For years, clinicians have used the labelling of specific proteins to diagnose tissue samples from tumors. Being able to specifically stain RNA in intact tumor samples opens up entirely new opportunities for clinical specimen diagnosis."

Per Uhlén, Principal Investigator, Professor at the Department of Medical Biochemistry and Biophysics at Karolinska Institutet

Working with pathologists and surgeons at Karolinska University Hospital, the researchers studied digital 3D images of tumors using advanced image processing software. In this way, they managed to identify each individual cell of a tumor and to analyse how the cells cluster as well as how specific cell populations arrange themselves in relation to the tumor's blood vessel structure. In another experiment, they studied the presence of so-called cancer stem cells in a highly aggressive form of breast cancer by specifically staining PROM1 RNA, a biomarker for cancer stem cells. Cancer tumors contain a very small number of cancer stem cells, which are thought to play a significant part in cancer formation. The DIIFCO method revealed small clusters of cancer stem cells deep inside the tumor samples from breast cancer patients.

COVID-19 samples next

Using the DIIFCO method, scientists can study RNA and proteins at a high resolution in all human tissue. The researchers are now planning to use their method to study tissue samples from COVID-19 patients. PCR analyses for detecting the RNA from the SARS-CoV-2 virus are frequently used in hospitals to test if patients have COVID-19, and the researchers now hope that the new imaging technique will be able to detect exactly where in the tissue the viral RNA is.

"Ours is one of the few labs in the world able to study intact tissue samples from humans," says Professor Uhlén. "This is particularly difficult when the tissue comes from elderly patients. I believe and hope that our method can provide important answers to where and how the new coronavirus attacks different organs."

Source:
Journal reference:

Tanaka, N., et al. (2020) Three-dimensional single-cell imaging for the analysis of RNA and protein expression in intact tumour biopsies. Nature Biomedical Engineering. doi.org/10.1038/s41551-020-0576-z.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
The association between handgrip strength and functional outcomes in long COVID-19